1232398-41-2Relevant academic research and scientific papers
2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation
Weinberg, Linda R.,Albom, Mark S.,Angeles, Thelma S.,Breslin, Henry J.,Gingrich, Diane E.,Huang, Zeqi,Lisko, Joseph G.,Mason, Jennifer L.,Milkiewicz, Karen L.,Thieu, Tho V.,Underiner, Ted L.,Wells, Gregory J.,Wells-Knecht, Kevin J.,Dorsey, Bruce D.
scheme or table, p. 7325 - 7330 (2012/02/04)
The JAK2/STAT pathway has important roles in hematopoiesis. With the discovery of the JAK2 V617F mutation and its presence in many patients with myeloproliferative neoplasms, research in the JAK2 inhibitor arena has dramatically increased. We report a nov
PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS
-
Page/Page column 408, (2010/08/05)
The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
